Yesterday, April 6, 2016, 45 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $197.78 to $2,952,262.40.

Highlighted Stocks Traded by Insiders:

Cognizant Technology Solutions (CTSH) - FREE Research Report

Ramakrishnan Chandrasekaran, who is Ex. Vice Chairman, Cog. India at Cognizant Technology Solutions, sold 17,036 shares at $62.13 on April 6, 2016. Following this transaction, the Ex. Vice Chairman, Cog. India owned 380,894 shares meaning that the stake was reduced by 4.28% with the 17,036-share transaction.

The shares most recently traded at $60.72, down $1.41, or 2.32% since the insider transaction. Historical insider transactions for Cognizant Technology Solutions go as follows:

  • 4-Week # shares sold: 13,937
  • 12-Week # shares sold: 14,764
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 57,523

The average volume for Cognizant Technology Solutions has been 4.9 million shares per day over the past 30 days. Cognizant Technology Solutions has a market cap of $37.3 billion and is part of the technology sector and computer software & services industry. Shares are up 2.58% year-to-date as of the close of trading on Wednesday.

Cognizant Technology Solutions Corporation provides information technology (IT), consulting, and business process services worldwide. The company operates through four segments: Financial Services, Healthcare, Manufacturing/Retail/Logistics, and Other. The company has a P/E ratio of 23.1. Currently, there are 17 analysts who rate Cognizant Technology Solutions a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTSH - FREE

TheStreet Quant Ratings rates Cognizant Technology Solutions as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and good cash flow from operations. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Cognizant Technology Solutions Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Egalet (EGLT) - FREE Research Report

Radie Robert S, who is President and CEO at Egalet, sold 5,000 shares at $6.99 on April 6, 2016. Following this transaction, the President and CEO owned 264,900 shares meaning that the stake was reduced by 1.85% with the 5,000-share transaction.

Melloy Deanne F., who is Chief Commercial Officer at Egalet, sold 860 shares at $6.96 on April 6, 2016. Following this transaction, the Chief Commercial Officer owned 33,420 shares meaning that the stake was reduced by 2.51% with the 860-share transaction.

The shares most recently traded at $7.00, up $0.04, or 0.57% since the insider transaction. Historical insider transactions for Egalet go as follows:

  • 4-Week # shares sold: 22,716
  • 12-Week # shares sold: 22,716
  • 24-Week # shares sold: 51,828

The average volume for Egalet has been 89,500 shares per day over the past 30 days. Egalet has a market cap of $174.8 million and is part of the health care sector and drugs industry. Shares are down 36.34% year-to-date as of the close of trading on Wednesday.

Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. Currently, there are 2 analysts who rate Egalet a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on EGLT - FREE

TheStreet Quant Ratings rates Egalet as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Egalet Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Commercial Metals (CMC) - FREE Research Report

Smith Barbara, who is Chief Operating Officer at Commercial Metals, sold 4,465 shares at $17.19 on April 6, 2016. Following this transaction, the Chief Operating Officer owned 200,019 shares meaning that the stake was reduced by 2.18% with the 4,465-share transaction.

The shares most recently traded at $16.54, down $0.65, or 3.93% since the insider transaction. Historical insider transactions for Commercial Metals go as follows:

  • 4-Week # shares bought: 7,500
  • 4-Week # shares sold: 1,100
  • 12-Week # shares bought: 7,500
  • 12-Week # shares sold: 1,100
  • 24-Week # shares bought: 7,500
  • 24-Week # shares sold: 1,100

The average volume for Commercial Metals has been 1.9 million shares per day over the past 30 days. Commercial Metals has a market cap of $1.9 billion and is part of the basic materials sector and metals & mining industry. Shares are up 21.04% year-to-date as of the close of trading on Wednesday.

Commercial Metals Company manufactures, recycles, and markets steel and metal products, and related materials and services in the United States and internationally. The stock currently has a dividend yield of 2.9%. The company has a P/E ratio of 14.9. Currently, there is 1 analyst who rates Commercial Metals a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CMC - FREE

TheStreet Quant Ratings rates Commercial Metals as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Commercial Metals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.